Darlene Dobkowski, Managing Editor for CURE® magazine, has been with the team since October 2020 and has covered health care in other specialties before joining MJH Life Sciences. She graduated from Emerson College with a Master’s degree in print and multimedia journalism. In her free time, she enjoys buying stuff she doesn’t need from flea markets, taking her dog everywhere and scoffing at decaf.
FDA Approves Elrexfio for Heavily Pretreated Relapsed/Refractory Multiple Myeloma
August 14th 2023The Food and Drug Administration granted accelerated approval for Elrexfio for the treatment of patients with relapsed or refractory multiple myeloma who previously received at least four lines of therapy.
FDA Approves Akeega Plus Prednisone for BRCA-Positive Prostate Cancer Subset
August 11th 2023Akeega, the first dual action tablet with a PARP inhibitor and abiraterone acetate, was approved for the treatment of patients with suspected or confirmed BRCA-positive metastatic castration-resistant prostate cancer.
Phase 3 Trial Launches to Assess EGFR Inhibitor for NSCLC Subset
August 4th 2023Researchers conducting this trial will compare zipalertinib plus chemotherapy with chemotherapy alone in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer with the EGFR exon 20 insertion mutation.
FDA Accepts Application for Zolbetuximab in Gastric, GEJ Cancers
July 10th 2023If the FDA approves zolbetuximab, this would mark the first CLDN18.2-targeting monoclonal antibody to treat patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Venclexta Plus Gazyva Induces Minimal Residual Disease, Improves Survival in CLL
July 9th 2023Fit patients with chronic lymphocytic leukemia treated with Venclexta and Gazyva, regardless of the use of Imbruvica, experienced improvements in progression-free survival and were more likely to obtain undetectable minimal residual disease.
Frailty Linked With Worse Outcomes, Functional Declines in Older Patients With NSCLC
July 5th 2023Patients 65 years and older with NSCLC and undergoing treatment with immunotherapy, chemotherapy and/or targeted therapy were more likely to have worse survival outcomes and declines in activity of daily living.
Alzheimer’s Disease Medication May Not Improve Cognitive Impairment in Breast Cancer Survivors
July 5th 2023Findings from a study conducted in women with a history of breast cancer demonstrated that treatment with donepezil, which is typically used to treat symptoms of Alzheimer’s disease and dementia, did not improve cognitive impairment, or “chemo brain.”